A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00929188 |
Recruitment Status :
Completed
First Posted : June 26, 2009
Last Update Posted : January 22, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Burning Pain, Crushing Pain, Migratory Pain, Radiating Pain, Splitting | Drug: JNJ-42160443 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | January 2015 |
Actual Study Completion Date : | January 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: 001
JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
|
Drug: JNJ-42160443
Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks |
Placebo Comparator: 002
Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
|
Drug: Placebo
Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1 |
- The change in the average cancer-related pain intensity score. [ Time Frame: From baseline (average cancer-related pain intensity score over the last 3 days before randomization) to the end of Week 4 (average cancer-related pain intensity score over the last 7 days of the double-blind treatment phase) ]
- Patient Global Impression of Change (PGIC) [ Time Frame: Up to Visit 10 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Terminally ill cancer patients as per judgment of the investigator (eg, patients who are in or who are candidates for hospice or palliative care for end-of-life management); Diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by standard pain treatments.
Exclusion Criteria:Planned major surgical procedures during the double-blind treatment phase that may affect study outcomes; Prior treatment with any other investigational NGF inhibitor therapy; Known allergies, hypersensitivity, or intolerance to JNJ-42160443 or its excipients; Enrolled in any investigational study within the previous 4 weeks or 5 half-lives of the investigational drug (whichever is longer), or are currently enrolled in another investigational study at the time of screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00929188
United States, Alabama | |
Birmingham, Alabama, United States | |
United States, Arizona | |
Tucson, Arizona, United States | |
United States, California | |
Laguna Hills, California, United States | |
Montebello, California, United States | |
San Diego, California, United States | |
United States, Florida | |
Miami, Florida, United States | |
Orlando, Florida, United States | |
United States, Georgia | |
Stockbridge, Georgia, United States | |
United States, Indiana | |
Anderson, Indiana, United States | |
United States, Kentucky | |
Lexington, Kentucky, United States | |
United States, Louisiana | |
Marrero, Louisiana, United States | |
Shreveport, Louisiana, United States | |
United States, Michigan | |
Farmington Hills, Michigan, United States | |
United States, North Carolina | |
Flat Rock, North Carolina, United States | |
United States, Ohio | |
Cleveland, Ohio, United States | |
United States, Utah | |
Orem, Utah, United States | |
United States, Virginia | |
Falls Church, Virginia, United States | |
France | |
Lille, France | |
Lyon, France | |
Suresnes, France | |
Toulouse, France | |
Villejuif, France | |
Poland | |
Bygdoszcz, Poland | |
Gdansk-Zaspa, Poland | |
Gdansk, Poland | |
Lodz, Poland | |
Warszawa, Poland | |
Wroclaw, Poland | |
Portugal | |
Almada N/A, Portugal | |
Coimbra, Portugal | |
Faro, Portugal | |
Lisboa, Portugal | |
Ponta Delgada, Portugal | |
Porto, Portugal | |
Setubal, Portugal | |
Spain | |
Barcelona N/A, Spain | |
Madrid, Spain | |
Palma De Mallorca, Spain | |
San Sebastián De Los Reyes, Spain | |
Terrasa Barcelona N/A, Spain |
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT00929188 |
Other Study ID Numbers: |
CR016057 42160443PAI2001 ( Other Identifier: Janssen Research & Development, LLC ) 2008-007690-21 ( EudraCT Number ) |
First Posted: | June 26, 2009 Key Record Dates |
Last Update Posted: | January 22, 2016 |
Last Verified: | December 2015 |
Moderate to severe chronic, cancer-related pain related to an active cancer Cancer-related pain Moderate to severe chronic pain JNJ-42160443 |
Cancer Pain Pain Neurologic Manifestations |